申请人:Ortho-McNeil Pharmaceutical, Inc.
公开号:EP1712550A2
公开(公告)日:2006-10-18
Use of substituted triazole diamine derivatives in the manufacture of a medicament for the treatment of a kinase mediated disorder wherein the disorder is mediated by the selective inhibition of at least one kinase selected from cyclin dependent kinase and a tyrosine kinase.
使用取代的三唑二胺衍生物制造治疗激酶介导的疾病的药物,其中该疾病是通过选择性抑制至少一种选自细胞周期蛋白依赖性激酶和酪氨酸激酶的激酶而介导的。